Target Selection and Qualification: The Case of Blister-Filling and Packaging Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Target Selection and Qualification: The Case of Blister-Filling and Packaging Systems
The authors propose an approach for qualification-target selection and show how it can be applied to blister-filling and packaging systems.


Pharmaceutical Technology
Volume 33, Issue 1, pp. 72-80

Toyohiko Takeda, PhD,* is chief of the good manufacturing practice committee, and Hiroshi Hirasawa is chief of the package subcommittee, both at the Japan Society of Pharmaceutical Machinery and Engineering, Miyoshi Bldg. 3F, 2-7-3, Kandata-cho, Chiyoda-ku, Tokyo, 101-0046, Japan, tel. +81 3 3252 3048, fax +81 3 3252 3049,

*To whom all correspondence should be addressed.

Submitted: June 22, 2008. Accepted: July 8, 2008.




What would you do differently? Email your thoughts about this paper to
and we may post them to the site.

References

1. ICH, ICH Q7A Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (Geneva, Nov. 10, 2000).

2. International Society for Pharmaceutical Engineering, "Commissioning and Qualification Baseline Guide" (ISPE, Tampa, FL, vol.5, 2001).

3. The Federation of Pharmaceutical Manufacturers' Associations of Japan, Qualification Practices of the Systems for Solid Dosage Forms for Internal Use—The Case of Pan Coating Systems (Japan Society of Pharmaceutical Machinery and Engineering, Tokyo, 2003).

4. The Federation of Pharmaceutical Manufacturers' Associations of Japan, Qualification Practices of the Systems for Solid Dosage Forms for Internal Use—The Cases of Blister Filling/Packaging Systems and Pillow Packaging Systems (Japan Society of Pharmaceutical Machinery and Engineering, Tokyo, 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here